InterStim¬Æ Amplitude Study  
Clinical Investigational Plan Version 2 .0 
23-Aug-2018 
[STUDY_ID_REMOVED]  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
MDT17030 Version 2.0 Page 1 of 61 
00HGWURQLF&RQILGHQWLDO
)Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWHClinical Investigation Plan 
Clinical Investigation Plan/Study Title InterStim¬Æ Amplitude Study 
Study Product Name [CONTACT_601434]/Local Sponsor [LOCATION_002] (Sponsor):
Medtronic, Inc.  
[ADDRESS_796363] NE 
Minneapolis, MN [ZIP_CODE] [LOCATION_003] 
Europe (Local Sponsor): 
Medtronic International Trading S√†rl Route du Molliau 31 
CH-1131 Tolochenaz, Switzerland 
Canada (Local Sponsor): 
Medtronic of Canada [ADDRESS_796364] 
Brampton, ON, L6Y 0R3 Canada 
[PHONE_2906] 
Document Version 2.0 / [ADDRESS_796365] know that it is 
confidential and that it may not be further disclosed by [CONTACT_476]. 

,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 2 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

 
  
 
 
 
 
 
 
  
 
  
 
 
  
 
 
  
 
 
 
 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 3 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

,QYHVWLJDWRU6WDWHPHQW
Participating investigators will be provided with a separate in vestigator agreement to document their 
obligations and commitment with  respect to study conduct. 
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 4 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

7DEOHRI&RQWHQWV
 ,QYHVWLJDWRU6WDWHPHQW    
7DEOHRI&RQWHQWV    
 *ORVVDU\    
 6\QRSVLV    
 ,QWURGXFWLRQ    
 %DFNJURXQG    
 3XUSRVH   
 2EMHFWLYHVDQG(QGSRLQWV    
 2EMHFWLYHV    
5.1.1. Primary Objective ...................................... ............................................................... ............. 18 
5.1.2. Seconda ry Objective..................................... ............................................................... .......... 18 
5.1.3. Addition al Measu res .................................... ............................................................... .......... 18 
 6WXG\'HVLJQ    
 'XUDWLRQ    
 5DWLRQDOH    
 3URGXFW'HVFULSWLRQ   
 *HQHUDO    
 0DQXIDFWXUHU    
 ,QWHQGHG3RSXODWLRQ    
 3URGXFW5HWXUQ    
 3URGXFW$FFRXQWDELOLW\    
 6HOHFWLRQRI6XEMHFWV    
 6WXG\3RSXODWLRQ    
 6XEMHFW(QUROOPHQW    
 ,QFOXVLRQ&ULWHULD    
 ([FOXVLRQ&ULWHULD    
 6WXG\3URFHGXUHV   
 6FKHGXOHRI(YHQWV    
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 5 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

 6XEMHFW6FUHHQLQJ    
 3ULRUDQG&RQFRPLWDQW2$%0HGLFDWLRQV   
 6XEMHFW&RQVHQW    
 5DQGRPL]DWLRQDQG7UHDWPHQ W$VVLJQPHQW   
 2$%0HGLFDWLRQ&RPSOLDQFH   
 $VVHVVPHQWRI(IILFDF\   
 $VVHVVPHQWRI6DIHW\   
 5HFRUGLQJ'DWD    
  'HYLDWLRQ+DQGOLQJ   
  6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ    
 5LVNVDQG%HQHILWV   
  3RWHQWLDO5LVNV   
  5LVNV2XWOLQHGLQWKH,QVWUXFWLRQVIRU8VH,)8   
  3RWHQWLDO%HQHILWV    
  5LVN%HQHILW5DWLRQDOH   
 $GYHUVH(YHQWVDQG'HYLFH'HILFLHQFLHV   
  'HILQLWLRQV&ODVVLILFDWLRQV   
  5HSRUWRI$GYHUVH(YHQWV   
  'HYLFH'HILFLHQFLHV   
  'HDWKV   
 'DWD5HYLHZ&RPPLWWHHV   
 6WDWLVWLFDO'HVLJQDQG0HWKRGV   
 *HQHUDO6WDWLVWLFDO& RQVLGHUDWLRQV  
13.1.1 Study Sample Size Justification ........................ ............................................................... ... 43 
13.1.2 Description of demographic and baseline variables ...... ................................................... 44 
13.1.3 Center  Pooling ......................................... ............................................................... ........... 44 
13.1.4 Missi ng Data ........................................... ............................................................... ............ 44 
13.1.5 Interim Analysis ....................................... ............................................................... ........... 44 
13.1.6 Reports ................................................ ............................................................... ............... 44 
13.1.7 Study S uccess .......................................... ............................................................... ............ 44 
13.1.8 Subgroup Analyses ...................................... ............................................................... ....... 44 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 6 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

13.1.9 Patient Populations .................................... ............................................................... ........ 44 
  3ULPDU\2EMHFWLYH    
6HFRQGDU\2EMHFWLYH    
  $GGLWLRQDO0HDVXUHV    
 (WKLFV    
  6WDWHPHQWVRI&RPSOLDQFH   
  3ULQFLSDO,QYHVWLJDWRU 2YHUVLJKW   
 6WXG\$GPLQLVWUDWLRQ   
  6SRQVRU    
  6LWH6HOHFWLRQ   
 &OLQLFDO7ULDO$JUHHPHQW  
  &XUULFXOXP9LWDH   
  0RQLWRULQJ   
  0HGWURQLF5HSUHVHQWDWLYH5ROH    
  'DWD0DQDJHPHQW   
  'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV    
  &RQILGHQWLDOLW\   
  /LDELOLW\    
  &,3$PHQGPHQWV   
  5HFRUG5HWHQWLRQ   
  3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ    
  6XVSHQVLRQRU(DUO\7HUP LQDWLRQ   
 5HIHUHQFHV    
 $SSHQGLFHV    
  $SSHQGL[$$GGLWLRQDO,QIRU PDWLRQIRU6LWHV   
  $SSHQGL[%,QVWLWXWLRQDO5HYLHZ%RDUGV(WKLFV&RPPLWWHHV   
  $SSHQGL[&3DUWLFLSDWLQJ,QYHVWLJDWRUVDQG,QVWLWXWLRQV   
  $SSHQGL[',QIRUPHG&RQVH QW0DWHULDOV   
 9HUVLRQ+LVWRU\    
 
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 7 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

*ORVVDU\
TERM  DEFINITION  
ADE Adverse Device Effect 
ADVANCED EVALUATION Therapy evaluation using InterStim Tined Lead  
AE Adverse Event 
AT As Treated 
AWC Adjusted Worst Case 
BASIC EVALUATION Therapy evaluation using tempo rary Test Stimulation Lead  
CC Complete Case 
CFR Code of Federal Regulations 
CIP Clinical Investigational Plan  
eCRF Electronic Case Report Form 
FAS Full Analysis Set 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
HIPAA Health Insurance Portability and Accountability Act 
ICF Informed Consent Form 
IDE Investigational Device Exemption 
IRB Institutional Review Board 
LOCF Last Observation Carried Forward 
NPU Neuro Programmer Upload 
OAB Overactive Bladder 
ICIQ-OABqol International Consultation on Incontinence Modular 
Questionnaire - Overactive Bladder Symptoms Quality of Life 
Questionnaire 
  
PNE Peripheral Nerve Evaluation 
QoL Quality of Life 
ORACLE RDC Oracle Remote Data Capture 
REPORTABLE ADVERSE EVENTS AND 
DEVICE DEFICIENCIES Serious, device-related, procedure-related, therapy-related 
adverse events and all device deficiencies will be considered 
reportable for this study 
SADE Serious Adverse Device Effect 
SAE Serious Adverse Events 
SAP Statistical Analysis Plan 
SENSORY THRESHOLD Sensory threshold is defined as the lowest amplitude where 
the subject first perceives sens ation of the stimulation in the  
perineum, perianal, vaginal, or any location deemed 
appropriate by [CONTACT_601411] a seated position.     
SNM Sacral Neuromodulation  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 8 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

TERM DEFINITION 
[LOCATION_003]DE Unanticipated Serious Adverse Device Effect 
UF Urgency Frequency 
UI Urinary Incontinence 
UUI Urinary Urge Incontinence 
US [LOCATION_002] 
UTI Urinary Tract Infection 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 9 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6\QRSVLV
Title InterStim Amplitude Study
Clinical Study Type Post-Market, On-Label  
Product Name [CONTACT_601435] (Model 3058) and In terStim Quadripolar Lead Model 
3889-XX (hereinafter referred to o nly as the tined lead or Mode l 
3889) with commercially-approved acc essories. Either the InterS tim 
Tined Lead Model [ADDRESS_796366] Stimulation Lead ( the 
lead is sold via Models [ADDRESS_796367] Stimulation Le ad) may be used for the 
therapy evaluation. 
In the rest of this document, ‚Äúa dvanced evaluation‚Äù will refer to 
therapy evaluation using InterStim Tined Lead and ‚Äúbasic evalua tion‚Äù 
will refer to therapy evaluation using temporary Test Stimulati on 
Lead. 
Sponsor  Medtronic, Inc. 
Indication under 
investigation  The indication under investigati on is overactive bladder (OAB).    
 
There are no investigational dev ices used in this study, all st udy 
products will be used in accordance with the product labeling. 
Investigation Purpose To assess the effect of three different amplitude settings (50%  of 
sensory threshold, 80% of sensory  threshold and s ensory thresho ld) 
on urinary urge inco ntinence (UUI).   
 
Sensory threshold is defined as the amplitude where the subject  first 
perceives the sensation of the s timulation in the perineum, per ianal, 
vaginal, or any location deemed appropriate by [CONTACT_601412] a seated position.    
Product Status  The InterStim II system is comme rcially approved for the treat ment of 
patients with OAB. 
Primary Objective To explore the effect of three different amplitude settings on urinary 
urge incontinence (UUI). 
Secondary Objective To characterize results from the  ICIQ-OABqol questionnaire for the 
three different amplitude settings.  
Additional Measures  to summarize safety 
for the three different a mplitude settings.   
Study Design This is a prospective, randomize d, multicenter, single-blinded study to 
explore the efficacy and quality of life (QoL) of [ADDRESS_796368] succe ssful 
therapy evaluation (50% improvement in UUI or UF voiding symptoms, or return to normal voiding of < 8 voids per day for UF 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 10 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

subjects) and qualify for a neuros timulator device implant in t he study 
will be randomized to one of th e [ADDRESS_796369] s will 
complete enrollment/baseline visi ts, lead implant, therapy eval uation, 
neurostimulator device implant, r andomization, 1-week follow-up  
visit, 6-week follow-up visit and 12-week follow-up visit.  
 
The total study duration for a s ubject is approximately [ADDRESS_796370] meet all eligibilit y criteria and demonstrate a s uccessful 
therapy evaluation prior to being randomized to one of three th erapy 
amplitudes: sensory threshold,  50% of sensory threshold or 80% of 
sensory threshold.   
Sample Size This study requires approximatel y 42 implanted and randomized 
subjects with 12-week follow-up  to be analyzed for the primary 
objective.  Approximately 60 subjects are estimated to be enrol led in 
the study with approximately 48 randomized; however, these 
numbers may vary to ensure that a minimum of 42 implanted 
subjects complete the study.  
Inclusion/Exclusion Criteria Inclusion Criteria: 
1.Primary diagnosis of urinary urge incontinence (UUI) as 
demonstrated on a 3-day baseline voiding diary 
demonstrating at least 3 UUI epi[INVESTIGATOR_1841] 
2.Female subjects 18 years of age or older 
3.Candidate for InterStim Lead Placement 
4.Willing and able to accurately complete voiding diaries, 
questionnaires, attend visits,  and comply with the study 
protocol (which includes maintenance of InterStim II programming settings over the course of the study) 
5.Willing and able to provide signed and dated informed 
consent  
6.Willing to maintain current reg imen (dosage and frequency) 
of any overactive bladder (OAB) medication  
 
Exclusion Criteria:    
1.Have neurological conditions such as multiple sclerosis, 
clinically significant periphe ral neuropathy or spi[INVESTIGATOR_105538]  
2.History of diabetes unless th e diabetes is well-controlled 
through diet and/or medications 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 11 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

3.Symptomatic urinary tract infection (UTI)  
4.Have primary stress incontinence or mixed incontinence 
where the stress component ove rrides the urge component 
5.Treatment of urinary symptoms with botulinum toxin in the 
past [ADDRESS_796371] botulinum toxin treatment 
during the study  
6.Implanted with a neurostimulator, pacemaker, or defibrillator 
7.Have knowledge of planned MR Is, diathermy, microwave 
exposure, high output ultrasonic exposure, or RF energy exposure not included within the scanning conditions provided with the MRI Guide lines for InterStim Therapy 
8.Women who are pregnant or planning to become pregnant  
9.Characteristics indicating a poor understanding of the study 
or characteristics that indicate the subject may have poor compliance with the study protocol requirements  
Currently enrolled or planning to enroll in a potentially 
confounding clinical study durin g the course of the study (co-
enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the Medtronic 
study manager (or designee)
Study Procedures and 
Assessments Study Visits:  
1.Enrollment / Baseline  
2.Tined Lead or temporary Test Stimulation Lead Implant  
3.Therapy Evaluation 
4.Tined Lead (if applicable) / Neurostimulator Device Implant 
(randomization procedures) 
5.One Week Follow-up Visit 
6.Six Week Follow-up Visit 
7.Twelve Week Follow-up Visit 
 
Enrollment/Baseline Subjects are considered enrolled at the time the study-specific  
informed consent is si gned.  Each subject must meet all the inc lusion 
and no exclusion criteria to be eligible to participate in the study.  At 
the enrollment/baseline visit, d ata will be gathered from subje cts 
including relevant medical history and concomitant OAB medicati on.  
 
Subjects will complete the following questionnaire: 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 12 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

xOveractive Bladder Symptoms Quality of Life 
Questionnaire    (ICIQ-OABqol)  
The voiding diary will be explai ned and given to the subject to  be 
completed for [ADDRESS_796372] Stimulation Lead Technical Manual. 
 
If using advanced evaluation, the InterStim tined lead  should be 
placed in accordance  with the InterStim Therapy Model 3889 Lead  
Implant Manual.   
 
For both advanced and basic eval uation, throughout the study, 
unilateral stimulation is required.  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Settings may be set pe r Investigator discretion during the ther apy 
evaluation period.   Any  reportable adverse events/device deficienci es will be documented and repor ted.  
 
Therapy Evaluation  
The therapy evaluation period should be conducted in accordance  
with the InterStim II System Labeling using the Verify¬Æ Externa l 
Neurostimulator.  The therapy evaluation period must not exceed  
either [ADDRESS_796373] Stimulation Lead or the approved duration in the  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 13 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

commercially available labeling in the respective country. A 3- day 
voiding diary will be completed t owards the end of the therapy 
evaluation period .   A minimum of a 50% improvement in voiding 
symptoms (either UUI or UF), or return to normal voiding of < 8  voids 
per day for UF subjects, is requi red in order to qualify for a 
neurostimulator implant in the study.  Any  
 reportable adverse events/ device deficiencies will be 
documented and reported.  
 
Tined Lead (if applicable) / Ne urostimulator Device Implant 
(randomization procedures) Once the subject qualifies for the neurostimulator device impla nt, site 
personnel may proceed with the Neurostimulator Device Implant V isit 
and randomization procedures.  If a subject does not qualify fo r the 
neurostimulator device implant, they will be exited from the st udy.  
For subjects who qualify for devi ce implant following a success ful 
basic evaluation, the InterStim tined lead should be placed in 
accordance with the InterStim Therapy Model [ADDRESS_796374] to one 
of the following therapy amplit udes: sensory threshold, 50% of 
sensory threshold or 80% of sens ory threshold.  Subjects are bl inded 
to their randomized setting.   All measures should be taken to ensure 
that the subject does not become unblinded to their randomizati on 
throughout the study.  
 
Subjects will be implanted with the Neurostimulator in accordan ce 
with the InterStim Therapy Inter Stim II Model 3058 Neurostimula tor 
Implant Manual.   
After the device implant is complete, it is required that subje cts be 
programmed to 14 hertz (Hz), 210 Œºs pulse width (pw) and contin uous 
stimulation for the duration of the study. During programming throughout the study, the subjec t‚Äôs sensory thre shold amplitude  will 
be determined by [CONTACT_601413]:  start at 0.05 volts (V) and 
increase voltage in 0.[ADDRESS_796375] eted during each study visit.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 14 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Following determination of sensor y threshold (seated position),  
amplitude will be programmed based on the assigned randomizatio n 
of sensory threshold, 80% of sen sory threshold, or 50% of senso ry 
threshold. Subjects will be allowe d to adjust amplitude +/- 0.0 5 V 
during the study.  Therapy amplit ude will remain at this level (¬± 0.05 
V) until the next follow-up visit  or programming session.     A ny 
 reportable adverse events will be 
documented and reported.  
  
1-Week Follow-up Visit   At the 1-week follow-up visit, any  reportable adverse events, d evice 
deficiencies and  will be collected.    
 
Prior to the completion of the v isit, the amplitude at each ele ctrode 
configuration that elicits a sen sory response must be determine d in 
 seated  positions.  Following determination of 
sensory threshold, amplitude will be programmed based on the 
assigned randomization.   
 Over the course of the study any  changes to programmed paramete rs 
(amplitude, PW, rate or cycling) outside of the allowable setti ngs in 
the study will be considered a pro tocol deviation; however, sub jects 
will be encouraged to continue in the study.    
 The voiding diary will be explai ned and given to the subject to  be 
completed approximately [ADDRESS_796376]‚Äôs voiding diary comp leted 
during the previous perio d will be collected.   
reportable adverse events, device deficiencies and other 
information will be collected from the subject.    
 
 
  
Prior to the completion of the v isit, the amplitude at each ele ctrode 
configuration that elicits a sen sory response must be determine d in 
 seated  positions. Following determination of 
sensory threshold, amplitude will be programmed based on the assigned randomization using the sensory threshold in the seate d 
position.   
 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 15 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

The voiding diary will be explai ned and given to the subject to  be 
completed approximately [ADDRESS_796377]‚Äôs voiding diary com pleted 
during the previous perio d will be collected.   
 reportable adverse events, de vice deficiencies and other 
information will be collected fro m the subject.  Prior to the 
completion of the visit, the ampl itude at each electrode config uration 
that elicits a sensory response must be determined in  seated 
 positions.  
 
Subjects will complete the following questionnaires: 
xICIQ-OABqol 
  
 
The subject is exited from the study after the 12-week follow-u p visit 
is complete.  Programming param eters after the subject has 
completed the study are at the Investigator‚Äôs discretion. 
 Unscheduled Visit   
If an unscheduled visit is needed  for any device-related reason , the 
amplitude at each electrode conf iguration that elicits a sensor y 
response must be determined in  seated  positions. Following determination of sensor y threshold, amplitude will be  
programmed based on the assigned randomization using the sensor y 
threshold in the seated position.   
 In addition to programming activities, , 
reportable adverse events and de vice deficiencies will be colle cted.  
 
Surgical Revision  
If a surgical revision is required after the full system implan t, the 
subject will be exited from the study.  
Safety Assessments Safety will be evaluated by [CONTACT_601414] e events 
and device deficiencies.  
 Statistics This study will explore the effe ct of three different amplitude  settings 
(50% of sensory threshold, 80% of  sensory threshold and sensory  
threshold) on UUI epi[INVESTIGATOR_914].   Change of average UUI epi [INVESTIGATOR_601387] 12-week follow-up from baseline will be assessed und er 
each amplitude setting.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 16 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

This study requires approximatel y 42 implanted and randomized 
subjects with 12-week follow-up to  be analyzed for the primary 
objective. Approximately 60 subj ects are estimated to be enroll ed in 
the study with approximately 48 randomized; however, these 
numbers may vary to ensure that a minimum of [ADDRESS_796378] deviation of 2.2 to 2.7 UUI epi[INVESTIGATOR_601388], with …≤—Åœ¨Õòœ¨œ±∆ö«Å≈Ω -sided and using a t-statistic to construct 
the confidence interval, a sampl e size of [ADDRESS_796379] deviation of 2.7. Precision is defined as one-half of the 
confidence interval (also known as the distance from the confid ence 
limits to the mean). This precision is less than our lowest ass umed 
treatment effect (1.8 UUI), so it is expected that the lower 95 % CI will 
be greater than [ADDRESS_796380] of each of three amplitude settings on UUI; however, the  
sample size is not sufficient for between group comparisons. 
 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 17 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

,QWURGXFWLRQ
 %DFNJURXQG
One of the most common patient co mplaints about sacral neuromod ulation (SNM) for overactive 
bladder (OAB) is unwanted or uncomfortable stimulation.1,2   It is often assumed that higher amplitude 
stimulation will provide better efficacy, but there is a lack o f clinical evidence regarding amplitude 
effects of SNM for OAB. However, there is some evidence that SN M for fecal incontinence is effective at 
sub-sensory threshold/amplitude.[ADDRESS_796381] of SNM is amplit ude-dependent. Using 
the rodent model of rhythmic bladder contractions (RBC), Su et al (2012) showed th at increasing 
amplitude of spi[INVESTIGATOR_601389] 3x motor threshold resulted in 
inhibition of bladder contractio ns by 20 to 90%, respectively.6  Similarly, using the RBC model in cats, 
Snellings and Grill ( 2012) showed that stimulation of the of th e pudendal nerves inhibited the frequency 
of contractions and increased bladder capacity at 0.8, 1, and [ADDRESS_796382] of neurom odulation on bladder function is amplitude-dependent. 
Duelund-Jakobsen et al (2013) demonstrated that there was no si gnificant difference in reduction of 
fecal incontinent epi[INVESTIGATOR_601390] 50% , 75%, and 100% of sensory 
∆ö≈ö∆åƒû∆ê≈ö≈Ω≈ØƒöÕæ≈∂—Åœ≠œµÕøÕò[ADDRESS_796383] of sub-sensory amplitude, it is 
important to understand the effica cy of SNM at different subsen sory and sensory threshold amplitudes. 
3XUSRVH
The purpose of this prospective,  multicenter, randomized, singl e-blind feasibility study is to explore the 
efficacy and quality of life unde r 3 different amplitude settin gs (sub-sensory amplitudes of 50% and 80% 
of sensory threshold and sensory  threshold).  Efficacy will be characterized with change from baseline 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 18 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

through [ADDRESS_796384] s are exited from th e study after the 12-
week follow-up visit is completed.    
2EMHFWLYHVDQG(QGSRLQWV
2EMHFWLYHV
3ULPDU\2EMHFWLYH
The primary objective in the stu dy is to explore the effect of three different amplitude settings (50% of 
sensory threshold, 80% of sensory  threshold and s ensory thresho ld) on number of UUI epi[INVESTIGATOR_914]  
6HFRQGDU\2EMHFWLYH
Secondary objective of this stu dy is quality of life (ICIQ-OABq ol) for the three different amplitude 
settings.  
$GGLWLRQDO0HDVXUHV
Additional measures include: 
xSafety 
  
  
6WXG\'HVLJQ
This is a prospective, multicent er, randomized, single-blind, f easibility study to explore the efficacy and 
quality of life of 3 different a mplitude settings in patients w ith UUI.  Subjects will remain blinded to their 
assigned randomization for the duration of the study.  
Eligible subjects will sign a study-specific informed consent f orm (ICF).  Following verification of eligibility 
criteria, subjects will go throug h therapy evaluation with the InterStim II System.  After qualifying for the 
device implant, the subject will proceed with a neurostimulator  device implant and randomization 
procedures.   Subjects will be ra ndomized to one of the three a mplitude settings:  50% of sensory 
threshold, 80% of sensory thresh old and sensory threshold.   
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 19 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Study requirements, including voiding diaries, quality of life questionnaires , and safety 
assessments will be completed as required in Figure 9-1: Study Visits.  The study is expected to last 
approximately [ADDRESS_796385] following the enrollment vis it.  Subjects will be exited from the 
study after the 12-week follow-up visit is complete.  
A minimum of forty-two implanted subjects (at least 14 subjects  per arm) who have completed the 12-
week follow-up visit are needed t o assess the study primary obj ective.  To account for screen failures, 
therapy evaluation conversion rate and loss to follow-up or mis sing data, it is anticipated that 
approximately 60 subjects will be consented and approximately 4 8 subjects will be 
implanted/randomized.  
The study will be conducted at a pproximately [ADDRESS_796386] em.  
'XUDWLRQ
Study subjects will be enrolled and will complete enrollment an d baseline assessments to determine 
eligibility for an InterStim lead implant procedure.  Subjects that do not meet eligibility criteria and/or 
qualify for a neurostimulator dev ice implant will be exited fro m the study.  All en rolled subjects that 
qualify for the study (meet all in clusion and no exclusion crit eria) will be randomized and undergo an 
InterStim II device implant procedure.  Post implant, subjects will be required to attend the 1-week 
follow-up visit (window +/- 3 da ys), 6-week follow-up visit (wi ndow +/- 7 days), and 12-week follow-up 
visit (window +/- 7 days).  The visits are expected to occur ov er approximately [ADDRESS_796387] 
approximately 18 months.  The completion of the study is define d as the approval of the Final Study 
Report and closure of all sites. 
5DWLRQDOH
While there is extensive literatur e on the safety and efficacy of SNM in patients with OAB, there is a 
paucity of published literature regarding amplitude programming , specifically programming to levels 
below sensory threshold.   The purpose of this study is to expl ore the effect of sensory and sub-sensory 
stimulation using the InterStim II System.  The InterStim II Sy stem is approved and will be used in 
accordance with commercially ava ilable product labeling for the  specific geography.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 20 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

3URGXFW'HVFULSWLRQ
 *HQHUDO
There are no investigational devices used in this study.   
The study will be conducted in th e US, Canada, and Europe, coun tries where the Neurostimulator Model 
3058 (InterStim II), ti ned lead model [ADDRESS_796388] Stimulation Lead (sold via Models 
305901, [ADDRESS_796389] Stimulation Lead)are 
commercially available as part of the InterStim system  (for th e treatment of OAB).  The [ADDRESS_796390] will be able to turn off the stimula tor or decrease amplitude if needed for 
safety reasons, and to make mino r increases to amplitude (if de sired).  
Labeling will be provided in acc ordance with local language and  regulatory requirements. 
0DQXIDFWXUHU
The products used in this study, identified in Section 7.1, are  manufactured by [CONTACT_13735], Inc. and are 
approved for use in treating patients with OAB.  
Manufacturer 
Medtronic, Inc. 
[ADDRESS_796391] 
Minneapolis, MN [ZIP_CODE] [LOCATION_003] 
,QWHQGHG3RSXODWLRQ
The study will enroll patients w ith a diagnosis of OAB and asso ciated symptoms of UUI.   All subjects 
implanted must be candidates for InterStim Therapy.  
3URGXFW5HWXUQ
Since all products are commercia lly available, standard commerc ial processes should  be used to return 
product (as applicable).   
3URGXFW$FFRXQWDELOLW\
All product used in the study are commercially available; there fore, no product accountability will be 
required for the study.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 21 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6HOHFWLRQRI6XEMHFWV
 6WXG\3RSXODWLRQ
The intended study population is  subjects diagnosed with OAB an d associated signs and symptoms of 
UUI.  
6XEMHFW(QUROOPHQW 
Subjects are considered enrolled at the time the study-specific  ICF is signed.  Each subject must meet all 
the inclusion criteria and no ex clusion criteria to be eligible  to participate in this study.  Any subject not 
meeting eligibility criteria will be excluded from study partic ipation.  Site personnel must complete logs 
related to recruitment and enrollm ent as required by [CONTACT_1758].   
,QFOXVLRQ&ULWHULD
To be eligible to participate in  the study, a subject must meet  all the following inclusion criteria:  
1.Primary diagnosis of urinary urg e incontinence (UUI) as demonst rated on a 3-day baseline 
voiding diary demonstrating at least 3 UUI epi[INVESTIGATOR_1841] 
2.Female subjects 18 years of age or older 
3.Candidate for InterStim Lead Placement  
4.Willing and able to accurately complete voiding diaries, questi onnaires, attend visits, and 
comply with the study p rotocol (which includes maintenance of I nterStim II programming 
settings over the co urse of the study) 
5.Willing and able to provide signed and dated informed consent  
6.Willing to maintain current regim en (dosage and frequency) of a ny overactive bladder (OAB) 
medication  
([FOXVLRQ&ULWHULD
A potential subject who meets an y of the following criteria wil l be excluded from participating in the 
study: 
1.Have neurological conditions such as multiple sclerosis, clinic ally significant peripheral 
neuropathy or spi[INVESTIGATOR_1828]  
2.History of diabetes unless the diabetes is well-controlled thro ugh diet and/or medications 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 22 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

3.Symptomatic urinary tract infection (UTI)  
4.Have primary stress incontinence or mixed incontinence where th e stress component overrides 
the urge component 
5.Treatment of urinary symptoms with botulinum toxin in the past [ADDRESS_796392] 
botulinum toxin treatment during the study  
6.Implanted with a neurostimulator, pacemaker, or defibrillator 
7.Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic 
exposure, or RF energy exposure not included within the scannin g conditions provided with the 
MRI Guidelines for InterStim Therapy 
8.Women who are pregnant or planning to become pregnant  
9.Characteristics indicating a poor understanding of the study or  characteristics that indicate the 
subject may have poor compliance with the study protocol requir ements  
10.Currently enrolled or planning to enroll in a potentially confo unding clinical study during the 
course of the study (co-enrollmen t in concurrent studies is onl y allowed when documented pre-
approval is obtained from the Me dtronic Study Manager (or desig nee)  
6WXG\3URFHGXUHV
The study schedule, procedures, and methods of assessment are d efined in detail to enable compliance 
with the required activities, and to ensure that the resulting data meet the criteria for evaluability.   See 
Figure 9-1 for Study Visit.  Ele ctronic case report forms (eCRF ) will be provided for use in collecting data 
for all subjects; the pertinent e CRFs along with the applicable  source documentation will be completed 
for each subject.  
The following study visits will be conducted: 
1.Enrollment / Baseline  
2.Tined Lead or temporary Test Stimulation Lead Implant  
3.Therapy Evaluation 
4.Tined Lead (if applicable) / Neurostimulator Device Implant (ra ndomization procedures) 
5.One Week Follow-up Visit 
6.Six Week Follow-up Visit 
7.Twelve Week Follow-up Visit 
 
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 23 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6FKHGXOHRI(YHQWV
Enrollment/Baseline 
Subjects are considered enrolled at the time the study-specific  informed consent is signed.  Each subject 
must meet all the inclusion and no exclusion criteria to be eli gible to participate in the study.  At the 
enrollment/baseline visits, data  will be gathered from subjects  including relevant medical and 
concomitant OAB medication histo ry.  Enrollment and Baseline Vi sit requirements wil l occur at separate 
visits.  
Subjects will complete the following questionnaire: 
xOveractive Bladder Symptoms Qualit y of Life Questionnaire (ICIQ -OABqol)  
The voiding diary will be explai ned and given to the subject to  be completed for [ADDRESS_796393] Stimulation  Lead Technical manual.     
If using advanced evaluation, the InterStim tined lead (model 3 889) should be placed in accordance with 
the InterStim Therapy Mode l 3889 Lead Implant Manual. 
 
 
 
 
 
   
 
 
 
 
 
 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 24 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

 
  
Settings may be set pe r Investigator discretion during the ther apy evaluation period and will be 
documented.   Any  reportable adverse events/device deficiencie s will be 
documented and reported.  
Therapy Evaluation  The therapy evaluation period sh ould be conducted in accordance  with the InterStim II System Labeling.  
The therapy evaluation period mus t not exceed either [ADDRESS_796394] Stimulat ion Lead as defined by [CONTACT_601415], or a new approved duration in 
an updated commercially availabl e labeling in the respective co untry. A 3-day voiding diary will be 
completed towards the end of t he therapy evaluation period .   A minimum of a 50% improvement in 
UUI or UF voiding symptoms, or re turn to normal voiding of < 8 voids per day for UF subjects, is required 
in order to qualify for a neurostimulator implant in the study.   Settings used during therapy evaluation 
will be documented during this visit.  Any  reportable adverse 
events/device deficiencies will be documented and reported.  
Tined Lead (if applicable) / Neur ostimulator Device Implant (ra ndomization procedures) 
Once the subject qualifies for the neurostimulator device impla nt, site personnel may proceed with the 
neurostimulator device implant and randomization procedures.  I f a subject does not qualify for the 
neurostimulator device implant, they will be exited from the st udy.  
For subjects who qualify for dev ice implant following a success ful basic evaluation, the InterStim tined 
lead should be placed in accordance with the InterStim Therapy Model [ADDRESS_796395] to one of the following th erapy amplitudes: sensory threshold, 
50% of sensory threshold or 80% of  sensory threshold.  Subjects  are blinded to their randomization.   All 
measures should be taken to ensu re that the subject does not be come unblinded to their randomization 
throughout the study.  
 
Subjects will be implanted with t he Neurostimulator in accordan ce with the InterStim Therapy InterStim 
II Model 3058 Neurostimul ator Implant Manual.   
After the device implant is complete, it is required that subje cts be programmed to 1 4 hertz (Hz), 210 Œºs 
pulse width (pw) and continuous s timulation for the duration of  the study.  During programming, the 
subject‚Äôs sensory threshold amplitude will be determined by [CONTACT_601416]:   start at 0.05 volts 
(V) and increase voltage using fine resolution in 0.[ADDRESS_796396] reports sensation.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 25 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Prior to discharge, the amplitud e at each electrode configurati on that elicits a sensory response must be 
determined in  seated  positions . To determine sensory threshol d, each electrode 
(0,1,2,3) will be programmed as t he cathode (negative) in a bip olar configuration in a systematic fashion.    
 Following determination of sens ory threshold, amplitude will be  programmed based on the assigned 
randomization of sensory threshold, 80% of sensory threshold, o r 50% of sensory threshold using the 
sensory threshold in a seated po sition.  As part of the program ming, impedance checks should be 
completed. Upon completion of programming, data will be collect ed via a programming printout or 
Neuro Programmer Upload (NPU).    
 
Subjects will be allowed to adj ust amplitude +/- 0.05 V during the study.  Therapy amplitude will remain 
at this level (¬± 0.05 V) until the next follow-up visit or prog ramming session.   Any  
 reportable adverse events/device deficiencies will be document ed and reported.  
1-Week Follow-up Visit   At the 1-week follow-up visit, any  reportable adverse events, d evice deficiencies  
 will be collected.    
During the visit, the subject‚Äôs sensory threshold amplitude wil l be captured by [CONTACT_601413]: 
start at 0.[ADDRESS_796397] be determined in  seated  posit ions. To determine 
sensory threshold, each electrode (0,1,2,3) will be programmed as the cathode (negative) in a bipolar 
configuration in a systematic fashion.    
Following determination of sensory threshold amplitude, amplitu de will be programmed based on the 
assigned randomization using sensory threshold in a seated posi tion.  Subjects will be  allowed to adjust 
amplitude +/- 0.[ADDRESS_796398] ed via a programming printout or 
NPU.    
Over the course of the study any  changes to programmed paramete rs (amplitude, PW, rate or cycling) 
outside of the allowable setting s in the study will be consider ed a protocol deviation; however, subjects 
will be encouraged to continue in the study.    
The voiding diary will be explai ned and given to the subject to  be completed approximately 3 days prior 
to the 6-week follow-up visit.   
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 26 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6-Week Follow-up Visit  
At the 6-week follow-up visit, t he subject‚Äôs voiding diary comp leted during the previous period will be 
collected.   reportable adverse events, device deficiencies and  other 
information will be collect ed from the subject.    
 
 
  
During the visit, the subject‚Äôs sensory threshold amplitude wil l be captured by [CONTACT_601413]: 
start at 0.[ADDRESS_796399] be deter mined in  seated  positions. To  determine sensory 
threshold, each electrode (0,1,2 ,3) will be programmed as the c athode (negative) in a bipolar 
configuration in a systematic fashion.    
 
Following determination of sens ory threshold, amplitude will be  programmed based on the assigned 
randomization using the sensory th reshold in the seated positio n.  Subjects will be  allowed to adjust 
amplitude +/- 0.[ADDRESS_796400]‚Äôs voiding diary com pleted during the previous period will be 
collected.   reportable adverse events, device deficiencies and  other 
information will be collected fro m the subject.  During the vis it, the subject‚Äôs sensory threshold will be 
captured by [CONTACT_601417]: start at 0.[ADDRESS_796401] be determine d in  seated  positions. 
To determine sensory threshold, each electrode (0,1,2,3) will b e programmed as the cathode (negative) 
in a bipolar configuration in a systematic fashion.     As part  of the programming, impedance checks 
should be completed. Upon completion of programming, data will be collected via a pr intout or NPU.   
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 27 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Subjects will complete the following questionnaires: 
xICIQ-OABqol 
  
The subject is exited from the study after the 12-week follow-u p visit is complete.  Programming 
parameters after the subject has completed the study are at the  Investigator‚Äôs discretion.  
Unscheduled Visit   If an unscheduled visit is neede d for any device-related reason , the subject‚Äôs sensory threshold 
amplitude will be confirmed by f ollowing this protocol: start a t 0.[ADDRESS_796402] be determined in  seated  
 positions. To determine sensory  threshold, each electrode (0,1 ,2,3) will be programmed as the 
cathode (negative) in a bipolar configuration in a systematic f ashion.     
Following determination of sensory threshold amplitude, amplitu de will be programmed based on the 
assigned randomization using the sensory threshold in a seated position.  Subjects will be allowed to 
adjust amplitude +/- 0.[ADDRESS_796403] will be exited from the study.   
 
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 29 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Table 9-1: Study Procedures 
Enrollment
/  Baseline Tined Lead 
or Test 
Stimulation 
Lead Implant Therapy 
Evaluation Tined Lead (if 
applicable)/ 
Neurostimulato
r Device Implant 1-Week
Follow-Up Visit 
(+/- 3 days) 6-Week
Follow-Up Visit 
(+/- 7 days) 12-Week
Follow-Up Visit 
(+/- 7 days) Unscheduled 
Visit  
Informed Consent  X*       
 
Randomization Procedures    X***     
Relevant Medical History X  
ICIQ-OABqol Questionnaire  X      
X  
Pregnancy Assessment X       
 
    
Assessment of Sensory Threshold  
X  
X X X X X 
PGI-I Questionnaire       
X X  
3-Day Voiding Diary X**  
X**   
X X X**** 
Device Interrogation/        
Programming Data   
X X X X X X X 
         
Assessment of Reportable Adverse 
Events and Device Deficiencies X X X X X X X X 
* Must occur prior to any st udy specific activities   
**50% improvement in UUI or UF vo iding symptoms, or return to n ormal voiding of < 8 voids per day for UF subjects, required fo r neurostimulator implant 
***Randomization must occur after study qualification; however,  may be prior to or after neurostimulator device implant  
****If the subject must be change d from their randomized arm, s ubjects should be encouraged to complete a 3-day voiding diary prior to the unscheduled visit.   
 
 
Note: Programming settings of 14 hz, 210 pw and continuous stim ulation are required following the neurostimulator device impla nt for the duration of the study 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 30 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6XEMHFW6FUHHQLQJ 
Subjects may be recruited throug h the investigator‚Äôs practice a nd referring physicians.
Potential subjects may be identi fied through chart reviews or a s new or existing patients attend clinic 
visits as appropriate.  If subjects are recruited from outside the investigator‚Äôs practice, sites are to 
ensure that appropriate release for access to the subject‚Äôs rec ords (paper and/or electronic) is obtained. 
Any subject recruitment materials disseminated to subjects (adv ertisements, handouts, posters, social 
media) must be approved by [CONTACT_1201]/EC prior to use.  
 
All subjects must be consented i n accordance wit h the protocol prior to any study-specific procedures. 
Recruited subjects will be screene d by [CONTACT_601418]‚Äôs inclusion and exclusion criteria.   
A screening log should be completed by [CONTACT_601419] a c umulative log of all screened subjects 
with reason for screening failure. 
 The Investigator will maintain a listing of all subjects enroll ed in the study. 

  
6XEMHFW&RQVHQW
The informed consent process will be performed in accordance wi th the ethical principles that have 
their origin in the Declaration of Helsinki, 21CFR¬ß50 Protectio n of Human Subjects (US only), SOR/98-
282 (Canada only) and in accorda nce with local regulatory requi rements.  No vulnerable patients will be 
allowed to be consented to par ticipate in the study. Data will be collected and treated in accordance 
with applicable Data Privacy Legislation. With regard to the EU  this includes Directive 95/46/EC and 
subsequent legislation. 
Prior to entering the study, the Principal Investigator [INVESTIGATOR_601391], procedures, expected study  duration, available alternative 
therapi[INVESTIGATOR_014], and the benefits and risks involved with study parti cipation and the potential treatment.   The 
person obtaining consent will av oid any coercion or undue impro per influence on, or inducement of, the 
subject to participate and the ICF will not waive, or appear to  waive, any legal rights.  Subjects will be 
given a copy of the IRB/EC appr oved ICF and will have ample tim e to review the document and to ask 
questions and will be informed of  their right to withdraw from the study at any time without prejudice; 
ICFs will be provided in a langu age understandable to the subje ct.  After this explanation and before any 
study-specific procedures have been performed, the subject will  voluntarily sign and personally date the 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 31 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

ICF.  Prior to participation in t he study, the subject will rec eive a copy of the signed and dated written 
informed consent and any other written information provided to the subject. 
The Principal Investigator [INVESTIGATOR_601392] (delegated) designee wi ll document the informed consent 
process, including the date of consent and name [CONTACT_60696] c onducting the consent process in the 
subject‚Äôs medical record.  A cop y of the signed ICF will also b e placed in the subjec t‚Äôs medical record.  
Throughout study participation, any significant new information  will be provided to the subject as 
outlined in the informed consent form.  As appropriate, the ICF  may be revised based on new 
information that becomes available.  
5DQGRPL]DWLRQDQG7UHDWPHQW$VVLJQPHQW
Once the subject meets all elig ibility criteria for the study, and has a successful the rapy evaluation, site 
personnel may proceed with the n eurostimulator device implant a nd randomization procedures.  If a 
subject does not meet all eligib ility criteria, subjects should  be exited and not proceed to the 
neurostimulator device implant and randomization procedures.  
At the time of the device implant, site personnel will obtain r andomization for one of the following 
therapy amplitudes: sensory thr eshold, 50% of sensory threshold  or 80% of sensory threshold.  
Randomization will be assigned in a 1:1:[ADDRESS_796404]‚Äôs randomization sequence on the Randomization eCRF whic h will be generated from the 
database.  
The investigator and research staff at the study site will be i nstructed to keep the subject blinded to 
their randomization; however, s ubjects may or may not feel stim ulation. The outcome measures in this 
study are based on the subject‚Äôs own assessment. Therefore, kee pi[INVESTIGATOR_601393] .  
 
During the study, subjects will be  encouraged to remain in the randomized treatment  arm; however, a 
subject may request to be re-programmed with a different amplit ude setting.  If this occurs, a protocol 
deviation will be required and  subjects should continue in the study and complete the remaining follow-
up visits.  

 
 
 
 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 32 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

 
  
$VVHVVPHQWRI(IILFDF\
Subject assessments will be perf ormed by [CONTACT_65398],  qualified and delegated site personnel 
according to the usual practices of the site. 
Urinary Voiding Diary 
Symptoms related to OAB will be evaluated using paper voiding d iaries.  Subjects will be trained to 
complete the urinary voiding diaries for 3-days as part of the baseline and therapy evaluation 
procedures.  The voiding diaries  will be completed at baseline,  therapy evaluation and prior to the 6 and 
12-week follow-up visits. Every effort should be made to remind  subjects of the importance of real-time 
diary completion. 
Voiding diary data will be used t o verify study inclusion crite ria for UUI epi[INVESTIGATOR_199325].  Diaries will 
also be used for comparison of e fficacy from 12-week follow-up visit to baseline for the primary study 
endpoint of UUI   
Assessments for Quality of Life Measures 
Subjects will complete the study  questionnaires confidentially on paper forms without site personnel 
consultation and these data will be entered to OC/RDC by [CONTACT_3725] p ersonnel.   Questionnaires should be 
completed prior to the follow-up visit when data is collected. Site personnel are encouraged to review 
forms for completeness. 
ICIQ-OABqol Questionnaire  
The ICIQ-OABqol is a robust, pat ient-completed questionnaire fo r evaluating quality of life (QoL) in 
patients with overactive bladder, for use in research and clini cal practice.9  The questionnaire used in the 
current study includes 26 questio ns which are 4-week recall for  symptom assessment.  
 
 
  
 
  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 33 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

$VVHVVPHQWRI6DIHW\
9.8.1 Reportable Adverse Eve nts and Device Deficiencies 
All reportable adverse events and device deficiencies will be c ollected throughout the study once the 
informed consent form is signed.  
5HFRUGLQJ'DWD
This study will be conducted using a remote data capture system .  The Oracle Clinical Remote Data 
Capture (RDC) system which allows  the study centers to enter st udy data into the sp onsor‚Äôs database 
over a secure internet connection, will be used to capture stud y required Case Report Form (CRF) 
information.  Data reported on v oiding diaries and subject ques tionnaires will be entered to the 
database by [CONTACT_8786].  Subj ects will complete the study q uestionnaires confidentially on paper 
forms without site personnel cons ultation and these data will b e entered to OC/RDC by [CONTACT_8786].  
Electronic CRFs (eCRFs) will be provided by [CONTACT_456]; requir ed data will be taken from source 
documents and directly entered into the study database via the CRFs by [CONTACT_14523], in 
accordance with applicable regulations.   
Device interrogation (programming ) data may be transmitted usin g either NPU or by [CONTACT_601420] a programming CRF.   
Subject voiding diaries and ques tionnaires are to be completed only by [CONTACT_423].  Representatives 
from the research site may not make entries to the diaries or q uestionnaires except for administrative 
clarification on source documentation.  
The Principal Investigator, Sub- Investigator, or an individual delegated by [CONTACT_079] [INVESTIGATOR_601394], are responsible  for documenting and entering data for 
the study on the eCRF s.  The Principal Investigator [INVESTIGATOR_54720]-Inve stigator is required to approve all data on 
CRFs via electronic signature. 
'HYLDWLRQ+DQGOLQJ
Protocol deviations are digressi ons from the written protocol d efined as an event where the clinical 
investigator or site personnel did not conduct protocol-require d procedures according to the study 
protocol.  Protocol deviations a re to be preapproved by [CONTACT_601421]/EC (as 
required) unless the deviation is  necessary to protect the heal th, safety, or welfare of a subject in an 
emergency situation.  The invest igator or delegated site person nel should contact [CONTACT_601422] l deviation; prior approval of deviations 
should be documented.  Prior approval is generally not required  if the deviation is due to an emergency 
circumstance or an unforeseen cir cumstance that is beyond the i nvestigator‚Äôs control; however, these 
deviations should be reported to  Medtronic and the IRB/EC (as r equired) after site personnel become 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 34 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

aware of the deviation.  Site pe rsonnel should work with subjec ts to ensure subject follow-up visits are 
scheduled within the visit window; however, any visits complete d outside of the visit window will 
require a protocol deviation to be reported.  All protocol devi ations must be reported on the Protocol 
Deviation eCRF after the site‚Äôs awareness of the deviation.    
The sponsor may choose to termin ate the study at a site for fai lure to follow the written protocol and 
investigator agreement.  If this occurs, the Investigator, IRB/ EC and governing regulatory authority (if 
applicable) will be notified in writing of the reasons for the termination. 
6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ
Subjects are free to voluntarily withdraw from the study at any  time and for any reason.   All implanted 
subjects will be followed until the 12-week follow-up visit, un less withdrawn from the study.  Withdrawn 
or exited subjects will be follo wed under normal medical practi ce.   
Examples of reasons for study di scontinuation include, but are not limited to, those listed below: 
xIf the subject does not meet eligibility criteria of at least 3  UUI epi[INVESTIGATOR_601395] a 3-
day baseline urinary voiding diary  
xSubject death 
xSubject lost to follow-up 
xSubject voluntarily withdraws from the study 
xSubject becomes pregnant 
xInvestigator terminates the subj ect‚Äôs participation in the stud y due to lack of compliance, 
violation of/change in eligibility criteria 
xAny clinical laboratory abnorma lity, current illness, or other medical condition or situation 
occurs such that continued study participation would not be in the best interest of the subject. 
xSubject is not a candidate for InterStim Therapy  
xNormal study completion  
 
Prior to deeming a subject lost t o follow-up, telephone calls m ust be documented in the subject‚Äôs 
medical record. If a minimum of three attempts to contact [CONTACT_941] s ubject have failed (e.g. phone and 
mailed letter), and no response is received, the site should ex it the subject and complete the Study Exit 
eCRF. 
When a subject is withdrawn fro m the study, the Study Exit eCRF  is to be completed and should include 
detailed notes as to why the subject was withdrawn from the stu dy (e.g., discomfort, lack of efficacy, 
diary too burdensome).  Withdraw n subjects will not be replaced .  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 35 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Once a subject completes partic ipation in the study, follow-up will continue in accord ance with the site‚Äôs 
standard of care.  No study spec ific medical care will be provi ded for a subject after discontinuation 
from the study, unless outlined in the Clinical Trial Agreement  and Informed Consent Form.  
5LVNVDQG%HQHILWV
3RWHQWLDO5LVNV
The risks outlined below are the same risks found in commercial  InterStim II System use; however, 
based on the amplitude settings, subjects may experience less t han desired improvements in OAB 
symptoms.  No additional study specific risks are present. 
5LVNV2XWOLQHGLQWKH,QVWUXFWLRQVIRU8VH,)8
Refer to the appropriate Instructions for Use (IFU) for the Int erStim System components for updated list 
on contraindications, precaution s, warnings, adverse events, di rections for use and other product 
specific details. 
In addition to the risks normally  associated with surgery, impl antation, or use of a neurostimulation 
system includes, but is not limited to, the following risks. Ce rtain adverse events may necessitate 
surgical intervention. 
Õªƒö«Äƒû∆å∆êƒûƒê≈öƒÇ≈∂≈êƒû≈ù≈∂«Ä≈Ω≈ùƒö≈ù≈∂≈êƒ®∆µ≈∂ƒê∆ö≈ù≈Ω≈∂Õæƒè≈Ω«Åƒû≈ØƒÇ≈∂ƒöÕ¨≈Ω∆å  bladder) 
Õª≈Ø≈Øƒû∆å≈ê≈ùƒê≈Ω∆å≈ù≈µ≈µ∆µ≈∂ƒû∆ê«á∆ê∆öƒû≈µ∆åƒû∆ê∆â≈Ω≈∂∆êƒû∆ö≈Ω∆ö≈öƒû≈ù≈µ∆â≈ØƒÇ≈∂∆öƒûƒö≈µƒÇ∆öƒû∆å≈ùƒÇ≈Ø∆ê ∆ö≈öƒÇ∆öƒê≈Ω∆µ≈Øƒö∆åƒû∆ê∆µ≈Ø∆ö≈ù≈∂  
device rejections 
Õª≈öƒÇ≈∂≈êƒû≈ù≈∂∆êƒû≈∂∆êƒÇ∆ö≈ù≈Ω≈∂≈Ωƒ®∆ê∆ö≈ù≈µ∆µ≈ØƒÇ∆ö≈ù≈Ω≈∂«Å≈ö≈ùƒê≈ö≈öƒÇ∆êƒèƒûƒû≈∂ƒöƒû∆êƒê∆å≈ùƒèƒûƒöƒÇ ∆ê∆µ≈∂ƒê≈Ω≈µƒ®≈Ω∆å∆öƒÇƒè≈ØƒûÕæ≈©≈Ω≈Ø∆ö≈ù≈∂≈ê  
or shocking) by [CONTACT_541270] 
Õª/≈∂ƒ®ƒûƒê∆ö≈ù≈Ω≈∂  
ÕªEƒû«Å∆âƒÇ≈ù≈∂  
ÕªPain at neurostimulator and or lead site 
Õª^ƒû∆å≈Ω≈µƒÇÕï≈öƒû≈µ≈Ω∆å∆å≈öƒÇ≈êƒûÕï≈öƒû≈µƒÇ∆ö≈Ω≈µƒÇ  
Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö≈ØƒûƒÇƒö≈Ω∆å≈∂ƒû∆µ∆å≈Ω∆ê∆ö≈ù≈µ∆µ≈ØƒÇ∆ö≈Ω∆å≈µ≈ù≈ê∆åƒÇ∆ö≈ù≈Ω≈∂≈Ω∆åƒû∆å≈Ω∆ê≈ù≈Ω≈∂  
Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö≈∂ƒû∆å«Äƒû≈ù≈∂≈©∆µ∆å«á  
Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö∆öƒûƒê≈ö≈∂≈ùƒêƒÇ≈Øƒöƒû«Ä≈ùƒêƒû∆â∆å≈Ωƒè≈Øƒû≈µ  
Õªd∆åƒÇ≈∂∆ê≈ùƒû≈∂∆öƒû≈Øƒûƒê∆ö∆å≈ùƒê∆ê≈ö≈Ωƒê≈¨  
 
The safety of SNM has not been established for pregnant women, for an unborn fetus, or during 
childbirth. This precaution is provided in the InterStim Therap y commercial labeling and should be 
adopted in this study; thus, no one who is pregnant or planning  to become pregnant will be enrolled. 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 36 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

If a subject learns or suspects t hat she is pregnant, the inves tigator will instruct her to turn her 
neurostimulator OFF and to visit  the study site as soon as poss ible; however, this will not be considered 
a reportable AE.  
3RWHQWLDO%HQHILWV
Subjects may not receive any dir ect medical benefit from partic ipation in this study but subjects will 
receive additional medical overs ight of treatment.  Participati on in this study may not provide greater 
benefit than if the subject was receiving InterStim Therapy out side of the study, as required study 
programming is within approved programming specifications.  Inf ormation from this study might help 
researchers further understand InterStim Therapy related to unc omfortable stimulation.  The benefit to 
subjects participating in this s tudy, and to future patients, r esides in the knowledge gained from this 
study. 
5LVN%HQHILW5DWLRQDOH
Participation in this study will not expose the subject to grea ter risks than if he/she were receiving 
InterStim Therapy outside of the study. There might be other di scomforts and risks related to InterStim 
Therapy and/or this study that are not foreseen at this time.  In addition, based on the amplitude 
settings, subjects may experience less than desired improvement s in OAB symptoms. 
The risks associated with InterS tim II System are minimized in this study by [CONTACT_601423], selecting an ap propriate patient population via 
inclusion/exclusion screening, a nd monitoring subject progress and events reported for this study. The 
review and minimization of the potential risks to the patient a nd the potential benefits to the patient 
support the conduct of this study. 
$GYHUVH(YHQWVDQG'HYLFH'HILFLHQFLHV
'HILQLWLRQV&ODVVLILFDWLRQV
Any adverse event meeting the def inition of: serious, device re lated, therapy related and/or procedure 
related as well as all device deficiencies will be considered r eportable for this study.   The term 
‚Äúinvestigational device‚Äù is part  of ISO14155 definitions.  The term ‚Äúinvestigational device‚Äù refers to any 
device used in the study including market released devices.  Ad verse events and device deficiencies are 
defined as follows: 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 41 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

if necessary request clarification and/or additional informatio n from the Investigator.  If Medtronic 
disagrees with the Investigator‚Äô s assessment of the adverse eve nt relationship to device, therapy and/or 
procedure, Medtronic study perso nnel will document the disagree ment and report or ensure reporting 
of both opi[INVESTIGATOR_534526]/EC as necessary.  All reported adverse events and device deficiencies will be 
reviewed by a Medtronic Medical Ad visor to ensure consistent re porting 
'HYLFH'HILFLHQFLHV
A device deficiency (DD) is an i nadequacy of a medical device w ith respect to its identity, quality, 
durability, reliability, safety or  performance. Device deficien cies include malfunctions, misuse or use 
errors, and inadequate labeling.  All device deficiencies must b e documented and submitted to 
Medtronic on the Device Deficiency eCRF. In addition, the Inves tigator must also determine and 
document on the eCRF device deficiencies that did not lead to a dverse event but could have led to a 
serious adverse device effect: 
–¨ if either suitable action had not been taken, 
–¨ if intervention had not been made, or 
–¨ if circumstances had been less fortunate 
'HDWKV
All subject deaths must be repor ted to Medtronic and the IRB/EC  as soon as possible, but no more than 
[ADDRESS_796405]‚Äôs death, regardless of whether or not the death is related to 
the device system or therapy. If limited information is known, the Adverse Event eCRF must be 
completed with available informat ion as soon as possible. As in formation becomes available, the eCRF 
will be updated. If the death occ urs at a location remote from the study site, it is the study site‚Äôs 
responsibility to make every attempt to retrieve all pertinent information related to the subject‚Äôs death 
and submit the investigator‚Äôs de ath summary of the known events  surrounding the death to Medtronic 
or its designee.  The Investigator should also attempt to deter mine, as conclusively as possible, whether 
such deaths are related to the d evice system, therapy, and/or p rocedure. If the death is evaluated as 
device, therapy and/or procedure related and unanticipated, the  event will be reported as a [LOCATION_003]DE by 
[CONTACT_601424] s.  In addition, the principal investigator 
[INVESTIGATOR_601396].  The principal investigator [INVESTIGATOR_601397]: 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 42 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

xDeath certificate 
xDeath summary/hospi[INVESTIGATOR_1097], if allowed by [CONTACT_54443]/local law 
xAutopsy report, if allowed by [CONTACT_54443]/local law 
All device system components that were being used at the time o f the death should be returned to 
Medtronic for analysis, if applic able. Any subject death will b e reported on the Adverse Event and Study 
Exit CRFs. 
'DWD5HYLHZ&RPPLWWHHV
This study will not use a Clinic al Events Committee or Data Mon itoring Committee.  Instead, all reported 
adverse events and device defici encies will be reviewed by a Me dtronic Medical Advisor to ensure 
consistent reporting as de fined in Section 11.2. 
6WDWLVWLFDO'HVLJQDQG0HWKRGV
*HQHUDO6WDWLVWLFDO&RQVLGHUDWLRQV
This study is a three-arm parall el design to explore effectiven ess, and quality of life under three 
amplitude settings. For the prim ary objective, the primary anal ysis will be performed in the complete 
case (CC) population, or the pop ulation of subjects who have da ta available at baseline and follow-up 
based on their randomization.  
Details of the primary and supporting analyses are outlined in the 
sections below.  
Continuous measures will be repo rted as N, means, medians, stan dard deviations, minimums and 
maximums. All summaries will be p rovided by [CONTACT_19313].  Categorical  measures will be reported in 
frequency distributions.  
Data analysis will be performed by  [CONTACT_13735]-employed statistic ians or designees. A validated statistical 
software package (e.g., SAS vers ion 9.2 or higher) will be used  to analyze the study results.  
The Statistical Analysis Plan (SAP) will be developed prior to data analysis and will include a 
comprehensive description of the statistical methods and report s to be included in the final study 
report. Any change to the data a nalysis methods described in th e CIP will require an amendment only if 
it changes a principal feature o f the CIP. Any other change to the data analysis methods described in the 
CIP, and the justification for making the change, will be descr ibed in the clinical study report.    
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 43 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6WXG\6DPSOH6L]H-XVWLILFDWLRQ
This study will explore the effect of three different amplitude  settings (50% of sensory threshold, 80% of 
sensory threshold, and sensory threshold) on UUI epi[INVESTIGATOR_11629] d ay. Change of average UUI per day at 
12-week follow-up will be assessed under each amplitude setting . This study requires approximately 42 
implanted and randomized subjects with 12-week follow-up data t o be analyzed for the primary 
objective. Assuming 10% attritio n after full system implant and  80% therapy evaluation success rate, 
approximately 48 subjects will be implanted and randomized in 3  arms.  However, these numbers may 
be exceeded to ensure that a m inimum of 42 subjects complete th e study. 
The objectives are descriptive in nature.   Confidence interval s will be calculated to describe the 
precision of the treatment effec t in each arm. Precision is def ined as one-half of the confidence interval 
(also known as the distance from  the confidence limits to the m ean). Sample size calculations were 
completed using the PASS 11 Confidence Intervals for One Mean m odule.  
From the randomized portion of the InSite study13, a mean reduction of 2.1¬±1.8 UUI epi[INVESTIGATOR_601398] 3 months in SNM subjects; and from the all impl anted cohort of InSite, a mean 
reduction of 2.3¬±2.[ADDRESS_796406] devia tion assumed (2.7), a sample si ze of [ADDRESS_796407] a 
precision of 1.56 (Table 13-1). This precision is less than our  lowest assumed treatm ent effect (1.8 UUI), 
so that it is expected that the lower 95% CI will be greater th an [ADDRESS_796408] 
deviation Precision 
2.2 1.27 
2.3 1.33 
2.4 1.39 
2.5 1.44 
2.6 1.5 
2.7 1.56 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 44 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

'HVFULSWLRQRIGHPRJUDSKLFDQGEDVHOLQHYDULDEOHV
Summary statistics will be provided, by [CONTACT_19313], for baseline and  demographic variables for subjects who 
are enrolled and randomized.  
&HQWHU3RROLQJ
Data from all study centers will be pooled for the analysis. Th ere are no planned statistical methods to 
test for treatment differences a mong centers. The study will be  conducted at approximately 20 centers 
in the [LOCATION_002], Canada and Europe.   
0LVVLQJ'DWD
Missing data imputations will not be performed.  
,QWHULP$QDO\VLV
No formal interim analysis is pl anned for this study.  Interim descriptive summaries may be performed; 
however, if provided, the study t eam, investigators and site pe rsonnel will be blinded to this 
information. No study decisions  will be made from descriptive s ummaries; therefore, no sample size 
adjustment is needed. 
5HSRUWV
A final report will be generated for this study.  Periodic prog ress reports may also be generated for the 
study.  
6WXG\6XFFHVV
As the study objective is to characterize the efficacy and QoL of 3 different amplitude settings, there is 
no pass/fail criteria propose d to define study success.  
6XEJURXS$QDO\VHV
Subgroup analyses will be detailed in the SAP, if any will be c onducted. 
3DWLHQW3RSXODWLRQV
The full analysis patient set (FA S) includes all subjects who s igned the study-specific ICF and enrolled in 
the study.  
The complete case (CC) patient set will consist of the subject set who have data ava ilable at baseline and 
follow-up.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 45 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

3ULPDU\2EMHFWLYH
3ULPDU\REMHFWLYH
To explore the effect of three different amplitude settings (50 % of sensory threshold, 80% of sensory 
threshold, and sensory threshold) on urinary urge incontinence (UUI) epi[INVESTIGATOR_914].  
Descriptive statistics for chang e in UUI from ba seline to 12 we eks will be provided in each randomized 
group.  
Negative values for a change from baseline represent an improve ment in UUI epi[INVESTIGATOR_601399].  
([SHULPHQWDOGHVLJQ
Subjects‚Äô number of UUI epi[INVESTIGATOR_601400] g diary. Data will be collected daily in the 
[ADDRESS_796409] and the average ch ange across all subjects in each group 
will be reported.  
(QGSRLQWVXFFHVVGHILQLWLRQ
This objective is to explore and characterize the reduction in number of UUI epi[INVESTIGATOR_601401].  There are no pass/fail criter ia proposed to define this endpoint 
success. 
$QDO\VLVPHWKRGV
Descriptive statistics including  mean, standard deviation, 95% confidence intervals, median, minimum 
and maximum will be provided.  
$QDO\VLVSRSXODWLRQVDQGVHQVLWLYLW\DQDO\VHV
The analysis population for this  objective will be on the CC po pulation, as described  in Section 13.1.9.   
In addition to the primary analys is, an as-treated (AT) sensiti vity analysis will be completed to assess the 
robustness of results. The AT a nalysis will include the populat ion of subjects who have data available at 
baseline and [ADDRESS_796410] of  each randomization group. Resp onder rates will be described as the 
percent of patients who achieve therapeutic success, defined as  ƒ± 50% reduction in average UUI 
epi[INVESTIGATOR_1841]/day from baseline to 12 weeks, divided by [CONTACT_77431] o f subjects included in the analysis. 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 46 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Responder rate analyses will be co mpleted based on the CC and A T analyses described above.  
6HFRQGDU\2EMHFWLYH
6HFRQGDU\REMHFWLYH
To explore the effect of three different amplitude settings (50 % of sensory threshold, 80% of sensory 
threshold, and sensory threshold) on quality of life with the I CIQ-OABqol Questionnaire.  
Descriptive statistics for the change in all domains of this qu estionnaire from baseline to 12 weeks will 
be provided in each randomized group. 
([SHULPHQWDOGHVLJQ
The change in each subscale score from Baseline to [ADDRESS_796411] and the 
average change across all subjec ts in each group will be report ed.  
(QGSRLQWVXFFHVVGHILQLWLRQ
This objective is to explore and  characterize the QoL under eac h amplitude setting from baseline to 12 
weeks. There are no pass/fail cr iteria proposed to define this endpoint success. 
$QDO\VLVPHWKRGV
Descriptive statistics including  mean, standard deviation, 95% confidence intervals, median, minimum 
and maximum will be provided.  
$QDO\VLVSRSXODWLRQVDQGVHQVLWLYLW\DQDO\VHV
The analysis population for th is objective will be on the CC po pulation, as described in Section 13.1.9.   
In addition to the primary analys is of the secondary objective,  an as-treated (AT) sensitivity analysis will 
be completed to assess the robustn ess of results. The AT analys is will include the po pulation of subjects 
who have data available at base line and 12 weeks, but will anal yze subjects according to the treatment 
they receive. 
 $GGLWLRQDO 0HDVXUHV
Additional measures have been added to provide relevant informa tion on parameters of interest in SNM 
therapy under different amplitude settings and to provide addit ional information.  
   
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 47 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Additional measures to summarize are:  
xIncidence of device-related, procedure-related and/or therapy-r elated adverse events 
  
  
Reportable device-related, procedure-related and/or therapy-rel ated adverse events will be 
summarized for subjects who are implanted and randomized under each amplitude setting. Device-
deficiencies will be summarized in the similar fashion. In addi tion, serious adverse events will be 
summarized. 
 
  
 
  
  
 
(WKLFV
6WDWHPHQWVRI&RPSOLDQFH
The study will be conducted in accordance with this protocol, t he ethical principles that have their origin 
in the Declaration of Helsinki have been implemented in this cl inical study by [CONTACT_600548], EC/IRB approval, study training, and risk bene fit assessment.  In addi tion, all applicable 
laws and regulatory requirements of the country/ies in which th e study is conducted will be followed 
and in accordance with GCP.    
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 48 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

xIn the US, the study will be con ducted in accordance with 21 CF R¬ß11 Electronic Records, 
Electronic Signatures, 21CFR¬ß50 Protection of Human Subjects, 2 1CFR¬ß56 IRB, and 
21CFR¬ß803 Medical Device Reporti ng.   Financial disclosures wil l be collected; however, this 
study is not considered a ‚Äúcove red study‚Äù under 21 CFR¬ß54 Finan cial Disclosure by [CONTACT_1615]. 
xIn Europe, the study will be conducted in accordance with regio nal or national regulations, as 
appropriate. 
xIn Canada, the study will be conducted in accordance with Canad a Medical Devices Regulations, 
1998 (SOR/98-282), and the Guidance  document for Mandatory Prob lem Reporting.  
Any additional requirements imposed by [CONTACT_1201]/EC or governing regulatory authority shall be followed, 
if appropriate. 
 Medtronic will distribute the appr oved version of the CIP and a ll other materials requ ired to conduct the 
study.  Prior to site activation, Medtronic will provide study training relevant and pertinent to the 
involvement of personnel conduct ing study activities and invest igator responsibilities.  Medtronic will 
not activate any site until the required approval/favorable opi [INVESTIGATOR_30757] 
(IRB)/Ethics Committee (EC) or no tification/approval from a reg ulatory authority have  been obtained, if 
appropriate.  
Site personnel must inform Medtronic of any change in  status of the IRB/EC a pproval once the site has 
started enrollment. 
3ULQFLSDO,QYHVWLJDWRU2YHUVLJKW
The Principal Investigator [INVESTIGATOR_601402] e nsure the study is conducted in 
accordance with all protocol requirements, all applicable regul atory requirements and any applicable 
institutional requirements rela ted to the conduct of clinical r esearch. The Princip al Investigator will 
ensure no study-related activities occur prior to regulatory an d IRB/EC approval.  Any actions taken by 
[CONTACT_1201]/EC with respect to the i nvestigation will be forwarded to Medtronic as soon as possible.  The 
Principal Investigator [INVESTIGATOR_601403]/or IRB/EC.  
Regulatory reporting of AEs/DDs w ill be completed according to local regulatory requirements. It is the 
responsibility of the Investigator to abide by [CONTACT_601425] A E/DD reporting requir ements stipulated by 
[CONTACT_1201]/EC responsible for overs ight of the study. Investigator s should report seri ous adverse events, 
device-, procedure- and therapy-re lated adverse events and devi ce deficiencies to Medtronic after the 
Investigator learns of the event in accordance with Table 14-1.   
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 49 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

In addition, Principal Investigator, or designated personnel wi ll provide Medtronic with the following 
minimum information related to s erious adverse events, device-,  procedure- and/or therapy-related 
adverse events and device deficiencies: 
xDate of adverse event or device deficiency 
xTreatment provided 
xResolution date 
xAssessment of seriousness 
xRelationship to the device, therapy and/or procedure 
Failure to perform the investigat or obligations or to complete corrective and preventive actions 
identified during monitoring or auditing activities may result in Principal Investigator [INVESTIGATOR_601404], and/or lead to  suspension or termination of t he study at the site. 
Table 14-[ADDRESS_796412] udy personnel will immediately report Adverse Eve nts and Device 
Deficiencies, related to a CE ma rked or FDA approved device use d during the study, to Medtronic‚Äôs 
Compliant Handling Unit who will ensure prompt review and appro priate reporting.   The Therapeutic 
Products Directorate is a divisi on of Heath Canada, and is resp onsible for regulating therapeutic 
products including Food, Drugs, Medical Devices, Natural Health  Products, Cells, Ti ssues and Organs and 
Cosmetics.  Table 14-1 includes minimum reporting requirements in Canada.  
  
Table 14-1 5HSRUWLQJ5HTXLUHPHQWV  
Serious Adverse Events (SAEs) 
Investigator submit to:  
Medtronic Europe: Immediately after the investigator first learns of the event or  of 
new information in relation wi th an already re ported event 
 
All other geographies: Report to the sponsor, without unjustified delay, all 
serious adverse events 
IRB/EC All geographies: Reporting timeframe as per local EC/IRB per local 
requirement 
Sponsor submit to:  
EC/IRB All geographies: Reporting timeframe as per local EC/IRB per local 
requirement 
Regulatory Authorities All geographies: Reporting timeframe as per local requirement 
Serious Adverse Device Effects ( SADEs), Unantici pated Serious D evice Effects ([LOCATION_003]DEs) and 
Unanticipated Adverse De vice Effects (UADEs) 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 50 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Investigator submit to:  
Medtronic US: As soon as possible to meet regulatory reporting requirements, but no 
later than 10 days after the date you become aware 
 
Europe:  Immediately after the investiga tor first learns of the event o r of 
new information in relation wi th an already re ported event 
 
All other geographies:  Submit as soon as possible af ter the Investigator first 
learns of the event, and per local requirements 
IRB/EC Reporting timeframe as p er local EC/IRB requirement 
Sponsor submit to:  
EC/IRB All geographies: Reporting timeframe as per local EC/IRB per local 
requirement  
Regulatory Authorities Canada (Medtronic of Canada Regul atory Compliance) to submit to  Health
Canada: As soon as possible to meet regulatory reporting requirements 
within 10 days after the date Medtronic becomes aware 
 
All other geographies: Reporting timeframe as per local requirement  
All Other Adverse Events 
Investigator submit to:  
Medtronic All geographies: Submit in a timely manner after the Investigator first 
learns of the event  
IRB/EC All geographies: Reporting timeframe as per local EC/IRB requirement  
Deaths 
Investigator submit to: 
Medtronic All geographies: All subject deaths must be r eported to Medtronic and the 
IRB/EC as soon as possible, but n o more than [ADDRESS_796413]‚Äôs death, regardless of  whether or not the death is re lated to the 
device system or therapy  
IRB/EC All geographies: All subject deaths must be r eported to Medtronic and the 
IRB/EC as soon as possible, but n o more than [ADDRESS_796414]‚Äôs death, regardless of  whether or not the death is re lated to the 
device system or therapy  
[LOCATION_003]DE, SADE, DD (Canada only) 
(referred to here as ‚Äúincidents‚Äù) occurring outside Canada requ iring corrective action or imposed by 
[CONTACT_601426]:  
Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) to submit re port to 
Health Canada: 
 
When Medtronic has indicated to a regulatory authority of the c ountry in 
which the incident occurred, int ention to take corrective actio n, or if the 
regulatory authority has required Medtronic to take corrective action. In 
this case, the incident must be reported to the Health Canada a s soon as 
possible after either Medtronic has reported to the local regul atory 
authority or a corrective action  has been imposed by [CONTACT_601427]
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 51 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

authority. 
Device Deficiencies that has resulted in an SAE (Canada only)  
Sponsor submit to: 
Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) to submit re port to 
Health Canada: As soon as possible to meet regulatory reporting 
requirements within 10 days after the date Medtronic becomes aware 
Device Deficiencies (DD) with SADE potentials 
Investigator submit to: 
Medtronic US & Europe:  Immediately after the investigator first learns of the 
deficiency or of new information in relation with an already re ported 
deficiency 
 
All geographies:  Report to the sponsor, without  unjustified delay, all device 
deficiencies that could have led  to a serious adverse device ef fect 
IRB/EC All geographies: Reporting timeframe as per local EC requirement 
Sponsor submit to:  
EC/IRB All geographies: Reporting timeframe as per local EC/IRB requirement 
Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) submits to H ealth
Canada: As soon as possible to meet regulatory reporting requirements 
within 30 days after the date Medtronic becomes aware 
 
All other geographies: Reporting timeframe as per local requirement 
All other Device Deficiencies 
Investigator submit to:  
Medtronic All geographies:  Submit in a timely manner after the investigator first 
learns of the deficiency 
IRB/EC All geographies: Reporting timeframe as per local EC requirement 
Withdrawal of IRB Approval  
Investigator submit to:  
Medtronic All geographies: Report a withdrawal of the reviewing EC/IRB approval 
within 
5 days of investigator notification 
Protocol Deviations for Emergency Reasons 
Investigator submit to:  
Medtronic US: Submit to Medtronic and IRB within 5 working days of the occur rence 
of an emergency deviation (made to protect the life or physical  well-being 
of a subject) 
 
Canada:  Per institutional guidelines, report protocol deviations to 
Medtronic 
EC/IRB US: Submit to Medtronic and IRB within 5 working days of the occurrence 
of an emergency deviation (made to protect the life or physical  well-being 
of a subject) 
 
Canada: Per institutional guidelines, re port protocol deviations to the  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 52 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

reviewing IRB 
Prior Notification of Protocol Deviations 
Medtronic All geographies:
Except in the occurrence of an em ergency deviation, the Investi gator must 
obtain prior approval from Medtro nic of protocol deviations. Pr ior approval 
from the IRB may also be required according to local requiremen ts. 
EC/IRB All geographies:
Except in the occurrence of an em ergency deviation, the Investi gator must 
obtain prior approval from Medtro nic of protocol deviations. Pr ior approval 
from the IRB may also be required according to local requiremen ts. 
Failure to Obtain Informed Consent 
Investigator submit to: 
Medtronic US and Europe: The Investigator must notify Medtronic within 5 working 
days upon awareness 
 
Canada: The Investigator must notify Medtronic within 5 working days after 
procedure 
EC/IRB US and Europe: The Investigator must notify the EC/IRB within 5 working 
days after upon awareness 
 
Canada: The Investigator must notify the EC/IRB within 5 working 
days after SURFHGXUH  
Final Report 
Medtronic US and Europe: Study reports must be submitted within 6 months after 
termination or completion of the  investigation or as required b y applicable 
regulation 
 
Canada: Study reports must be submitted within 3 months after 
termination or completion of the  investigation or as required b y applicable 
regulation  
EC/IRB US and Europe: Study reports must be submitted within 6 months after 
termination or completion of the  investigation or as required b y applicable 
regulation 
 
Canada: Study reports must be submitted within 3 months after 
termination or completion of the  investigation or as required b y applicable 
regulation 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 53 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

6WXG\$GPLQLVWUDWLRQ
 6SRQVRU
This study is sponsored by: 
[CONTACT_13735], Inc.  
[ADDRESS_796415] of sponsor‚Äôs study staff wi ll be provided as a separate document to site personnel.  Sponsor will 
maintain an updated list of contact [CONTACT_3031].  
6LWH6HOHFWLRQ
The role of the principal investigator [INVESTIGATOR_601405]-to-day cond uct of the study as 
well as ensure data integrity and the rights, safety and well-b eing of the patients inv olved in the study.  
Site selection criteria will be documented and utilized to ensu re adequate site selection.   
&OLQLFDO7ULDO$JUHHPHQW
A Clinical Trial Agreement shall be in place, signed by [CONTACT_601428]/or principal 
investigator [INVESTIGATOR_601406], as per the local legal  requirements, and returned to Medtronic 
prior to the commencement of any  study activities. The investig ator is indicating approval of the Clinical 
Investigation Plan and subsequent amendments, by a fully execut ed agreement.  
&XUULFXOXP9LWDH
A curriculum vitae from each Investigator part icipating in the study shall be obtained.  
0RQLWRULQJ
Medtronic is responsible for ens uring the proper conduct of thi s study in terms of adherence to 
applicable regulations, protocol  compliance, and the validity a nd accuracy of the study data entered on 
CRFs.  The Principal Investigato r, his/her delegate(s) and the study coordinator(s) shall be accessible to 
Medtronic field personnel and t he Clinical Study Manager. The P rincipal Investigator and site personnel 
will provide the Medtronic moni tor(s) with complete access to p rimary source data o r certified copi[INVESTIGATOR_014] 
(e.g., paper and electronic hospi [INVESTIGATOR_307]/clinical charts, appointme nt books, laboratory r ecords) that support 
the data on the CRFs as well as  other documentation supporting the conduct of the study.  The monitor 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 54 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

will perform source data verification and routine reviews of st udy-related regulatory documents during 
scheduled monitoring visits and wo rk to secure compliance shoul d any deficiencies be observed. The 
monitoring plan contains the str ategy for frequency of monitori ng visits and source d ata verification to 
be performed for this study. 
0HGWURQLF5HSUHVHQWDWLYH5ROH
Medtronic representatives may pa rticipate in the conduct of the  study to the extent listed below.   
Medtronic representatives can pr ovide technical support to the investigator and other health care 
personnel as needed during study  visits.  This support may incl ude the training of site personnel on use 
of the Medtronic equipment or the protocol-related procedures a nd forms. 
In addition, Medtronic personnel can perform certain activities  to ensure study quality.  These activities 
may include: 
xObserving testing or medical procedures to provide information relevant to protocol completion 
xReviewing collected data and study documentation for completene ss and accuracy 
xPerform device programming or device interrogation under the di rection of the investigator(s) 
Medtronic personnel will not: 
xPractice medicine 
xProvide medical diagnosis or treatment to subjects 
xDiscuss a subject‚Äôs condition or treatment with a subject witho ut the approval and presence of 
the health care provider. 
xComplete CRFs or make entries in the subject‚Äôs medical record 
'DWD0DQDJHPHQW
Medtronic personnel will perform  routine edit and consistency c hecks for items such  as missing data or 
inconsistent data.  Identified data inconsistencies will be res olved by [CONTACT_249020]; 
investigators and site personnel will review data discrepancies  and respond to the discrepancies in a 
timely manner.  The resolved disc repancy will become a part of the eCRF record for the subject. 
The Oracle Clinical Remote Data Capture (RDC) system which is 2 1CFR¬ß11 Part E compliant controls user 
access, and ensures data integrit y. This system is a fully vali dated system. The RDC system maintains an 
audit trail of entries, changes or corrections in eCRFs. User a ccess will be granted to each individual 
based on his or her delegation o f authority and completion of r equired training. If a person only 
authorized to complete eCRFs mak es changes to an already signed  eCRF, the system will require the 
Principal Investigator, or authorized delegate, to re-sign the eCRF. 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 55 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

The Principal Investigator, or d esignated representative, is re sponsible for the data submitted and must 
review all data for accuracy and provide his/her approval of th e eCRF and sign each form with an 
electronic signature.  
'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV
Source data is all information, o riginal records (or certified copi[INVESTIGATOR_014]) of clinical findings, observations or 
other activities in a study necessary for the reconstruction an d evaluation of the study. Examples of 
these originaldocuments and reco rds include, but are not limite d to: hospi[INVESTIGATOR_307]/clinic records, phone 
records, laboratory reports, etc .   Site personnel should clear ly indicate the subjects‚Äô participate in the 
study within the medical records.  
Principal Investigator [INVESTIGATOR_601407]-relate d monitoring, audits , IRB/EC review and 
regulatory inspections(s) by [CONTACT_601429]/documents.  Medtronic or third-party 
auditors representing Medtronic may perform clinical site audit s to verify the performance of the 
monitoring process and study co nduct, and to ensure compliance with applicable regulations.  
Representatives for regulatory b odies such as the FDA may also perform site inspections related to this 
clinical study.  The Principal I nvestigator, site personnel, an d institution will provide auditors with direct 
access to primary source data and  all study-related documentati on.  
In accordance with GCP and regula tory requirements, Medtronic w ill investigate suspected cases of 
fraud. 
&RQILGHQWLDOLW\
Subject confidentiality is assur ed through the use of subject i dentification numbers, and the de-
identifying of photocopi[INVESTIGATOR_601408].  In addition to the review of records on 
site, release of de-identified records to Medtronic may be nece ssary, such as in the evaluation of 
adverse events.   
For purposes of monitoring this s tudy, access to clinic and hos pi[INVESTIGATOR_601409], agents of Medtronic (e.g. CRO), the FDA, and other r egulatory agencies.   
Health Insurance Portability and  Accountability Act (HIPAA) lan guage will be required to be included at 
every site in the US.  HIPAA language may be included within th e US ICF template.  
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 56 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

/LDELOLW\
 6WXG\)XQGLQJ
The costs associated with study c onduct will be documented in s eparate Clinical Trial Agreements that 
will be signed by [CONTACT_13735], the Principal Investigator, and/or  the management of the institution. 
Subject compensation (if applicable) is detailed in the Patient  Informed Consent Form. 
 ,QVXUDQFH
Medtronic of Canada, Lt d., Medtronic International Trading SARL , and Medtronic Logistics LLC are 
wholly owned subsidiaries of Medt ronic, which as the parent com pany of such entities maintains 
appropriate clinical study liab ility insurance coverage as requ ired under applicable laws and regulations 
and will comply with applicable l aw and custom concerning speci fic insurance coverage. If required, a 
Clinical Trial Insurance statement/certificate will be provided  to the EC, governing regulatory authority 
(if applicable) and/or the IRB.  
 :DUUDQW\
Warranty information is provided in the product packaging for c ommercially available products. 
 ,QGHPQLILFDWLRQ
Indemnification language will be contained in the Clinical Tria l Agreements. 
&,3$PHQGPHQWV
Protocol amendments may be initi ated by [CONTACT_601430].  
Protocol amendments must be approved by [CONTACT_601431]/EC  and governing 
regulatory authority (if applicab le); protocol amendment approv al and approval of any associated 
changes to the informed consent document must be obtained prior  to implementation of the 
amendment except: 
xWhen necessary to eliminate an immediate/or apparent immediate hazard to participating 
subjects 
xWhen the change involves purely administrative or logistical as pects of the study 
5HFRUG5HWHQWLRQ
At a minimum, the investigator i s responsible for the preparati on, review, and retention of the records 
listed below: 
xEssential correspondence that p ertains to the investigation 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 57 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

xRecords of each subject‚Äôs case h istory and exposure to the devi ce.  Case histories include the 
CRFs and supporting data (sour ce documentation), such as: 
R Signed and dated ICFs 
R Medical records, including, for example, progress notes of the physicians, the 
subject‚Äôs hospi[INVESTIGATOR_3853] (s) and the nurses notes 
R All reportable adverse event information 
R Data related to the SNM therapy session  
xDocumentation of any deviation to the protocol, including the d ate and the rati onale for such 
deviation 
xSigned Investigator Agreement and curriculum vitae for all Inve stigators 
xThe protocol and any amendments 
The Principal Investigator [INVESTIGATOR_601410] a minimum of 2  years following completion of  the study or longer i f required per local 
regulations.  Medtronic will be n otified in writing of any tran sfer of study documentation.   
3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ
This feasibility study will provid e an initial understanding of  various amplitude stimulation settings and 
impact on symptoms.  The study will be registered on clinicaltr ials.gov and the results of the study may 
be published.  
6XVSHQVLRQRU(DUO\7HUPLQDWLRQ
Medtronic reserves the right to suspend or terminate the study at any time.  Reasons may include, but 
are not limited to, the following: 
xInsufficient enrollment to complete the study within the expect ed timeframe 
xIdentification of unacceptable sa fety profile; suspi[INVESTIGATOR_248940] a 
suspension, confirmation of an unacceptable risk will result in  termination 
xProduct performance/product supply issues  
Medtronic reserves the right to suspend or terminate the study at an individual site.  Reasons may 
include, but are not limited to, the following: 
xNoncompliance with the protocol  
xSerious or repeated deviations at the site 
xFailure to implement required corrective and preventive actions  
xInsufficient enrollment to compl ete the study wi thin the expect ed timeframe 
xLoss of appropriately trained site personnel 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 58 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

Investigators are required to not ify the IRB/EC and governing r egulatory authority (if applicable) of study 
suspension/termination.  Subjects  will be notified by [CONTACT_601432]/termination due to 
unacceptable risk or of termination due to any other cause. 
,QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ
 
MDT17030 Version 2.0 Page 59 of 61 
00HGWURQLF&RQILGHQWLDO
 )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH

5HIHUHQFHV
1.   Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, Hassouna MM, Jonas U, 
van Kerrebroeck PE, Lycklama a Ni jeholt AA, Oleson KA, Schmidt RA. Long-term results of a 
multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, 
urgency-frequency, and retent ion. Urology 56: 87-91. 2000.  
2.   Noblett K, Benson K, and Kred er K. Detailed analysis of adve rse events and surgical Interventions 
in a large prospective trial of sacral neuromodulation therapy for Overactive bladder patients. 
Neurourology Urodynamics 36:1136-1139. 2017. 
3.   Duelund-Jakobsen J, Buntzen S, Lundby, Laurberg S. Sacral ne rve stimulation at subsensory 
threshold does not compromise tr eatment efficacy: results from a randomized, blinded 
crossover study. Ann Surg 257: 219-223. 2013. 
4.   Gleason JL, Kenton K, Greer WJ, Ramm O, Szychowski JM, Wilso n T, Richter HE.  Sacral 
neuromodulation effects on periurethral sensation and urethral sphincter activity. Neurourology 
Urodynamics. 32(5):476-9. 2013. 
5.   h≈Ø∆µƒöƒÇ≈íKÕï<≈Ωƒê≈ö^DÕïs≈Ø≈ùƒû≈êƒû≈∂Z&Õïƒû≈©≈Ω≈∂≈ê,Õï«ÄƒÇ≈∂'ƒû≈µƒû∆å∆öt'ÕïƒÇƒû∆öƒû≈∂ 'Õò Sacral 
neuromodulation: does it affect the rectoanal angle in patients  with fecal incontinence? World J 
Surg. 34(5):1109-14. 2010. 
6.   Su X, Nickles A, Nelson DE. Optimization of Neuromodulation for Bladder Control in a Rat Cystitis 
Model. Am J Physiol Renal Physiol 302: F477-486. 2012a. 
7.   Snellings AE and Grill WM. Effects of stimulation site and s timulation parameters on bladder 
inhibition by [CONTACT_601433]. BJU Int 110: 136-14 3. 2012. 
8.   Gill B, Pi[INVESTIGATOR_7988]-Berdichevsky J, Bhattacharyya P, Brink TS, M arks B, Quirouet A, Vasavada, S, Jones 
SE and Goldman HB.  Real-time changes in brain activity during sacral neuromodulation for 
overactive bladder.  J Urol, In Review. 2017. 
9.   Coyne, K., Revicki, D., Hunt, T ., Corey, R., Stewart, W., Be ntkover, J., Kurth , H., Abrams, P. 
Psychometric validation of an ov eractive bladder symptom and he alth-related quality of life 
questionnaire: the OAB-q. Qual.Life.Res.  2002; 11(6); 563-574. 
10.Vecchioli-Scaldazza C, Morosetti  C, Berouz A, Giannubilo W, Fer rara V. Solifenacin succinate 
versus percutaneous tibial nerve stimulation in women with over active bladder syndrome: 
Results of a randomized controll ed crossover study. Gynecologic  and Obstetric Investigation 
2013; 75(4):230-234. 